Targeted therapies such as PARP and VEGF inhibitors are currently being used in ovarian cancer in the adjuvant setting and have been recently investigated in a maintenance therapy setting, although PARP inhibition may only be effective in a small subset of patients, for example, those with homologous DNA damage repair defects (BRCA). This evidence concerns the gene VEGFA and ovarian cancer.